2026 - industry facts

Breaking into a new market means re-qualifying with OEMs and Tier-1s (PPAP/IATF audits, traceability, warranty risk), and that process can stall for months even when your product is strong. On top of that, tariffs, origin rules, and shifting sourcing strategies can erase your margin or disqualify you before you even get a serious RFQ.

Entering a new market is slow because regulatory pathways, clinical evidence expectations, and quality-system audits (ISO 13485/MDSAP/FDA-style) create long lead times before revenue starts. Meanwhile, distributor dependence, tender dynamics, and reimbursement/local compliance can block adoption even after you’re technically “approved.”

New-market expansion is brutal because tariffs, trade remedies, and origin scrutiny can instantly change your landed cost and even restrict which buyers will touch your product. At the same time, bankability requirements, certification timelines, and utility/installer qualification processes delay projects and push customers toward “already approved” suppliers.

Winning new markets is hard because plastics is margin-thin and buyers compare you on total landed cost, consistency, and delivery performance—so any tariff, resin volatility, or freight swing can make you uncompetitive overnight. And without local certifications, QA documentation, and repeatable process control, procurement won’t take the risk of switching to you at scale.